Skip to main content

Market Overview

Regeneron's Lower Dose Of COVID-19 Antibody Cocktail Cuts Hospitalization, Death By 70%


Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced that even a lower-than-authorized dose of its combination of monoclonal antibody (mAbs) reduced hospitalization or death by 70% in non-hospitalized COVID-19 patients.

  • The company seeks emergency use approval for the lower dose.
  • The placebo-controlled trial of more than 4,500 people showed casirivimab, and imdevimab reduced the risk of hospitalization or death by 70% for the 1,200 mg IV dose and 71% for the authorized 2,400 mg IV version when compared to placebo.
  • The antibody cocktail also met all key secondary endpoints in the Phase 3 trial, including reducing symptom duration to 10 days from 14.
  • A companion Phase 2 trial showed that even the lowest doses tested as low as 300 mg IV had significant viral load reductions over the first 7 study days, comparable to the 2,400 mg and 1,200 mg IV doses.
  • Roche Holdings AG (OTCMKT: RHHBY) is responsible for sales outside the U.S.
  • Regeneron expects to record approximately $260 million in REGEN-COV U.S. net product sales to the U.S. government in the first quarter of 2021.
  • According to recently updated U.S. fact sheets for all authorized monoclonal antibody treatments, indicated that REGEN-COV was able to retain potency against key emerging variants.
  • Price Action: REGN shares closed 2% higher at $483.2 on Monday.

Related Articles (REGN + RHHBF)

View Comments and Join the Discussion!

Posted-In: COVID-19 CoronavirusBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at